Stay updated with breaking news from Database Consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, ...
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
The combination of durvalumab and guadecitabine generated early signs of clinical activity and tolerability in patients with advanced clear cell renal cell carcinoma, particularly those with no prior exposure to checkpoint inhibitors.
PFS improved with cabozantinib + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma.
Randomized study shows 'clinically meaningful' PFS improvement over dual immunotherapy alone